Communicable Disease Reporting
Communicable Disease Reporting Rule
- 2015 Communicable Disease Reporting Rule
- Requirements for Laboratory Reporting of COVID-19 Test Results (updated April 4, 2022)
- COVID-19 Control Measures (updated Feb. 23, 2022)
- Local Health Department Guidance on Communicable Disease Laws (updated July 26, 2021)
How to Report
Immediately reportable conditions should be called to the IDOH Epidemiology Resource Center at 317-233-7125 (8:15 am – 4:45 pm EST) or 317-233-1325 (after hours, weekends, holidays).
All other conditions should be reported via Morbidity Report in NBS or via the specific reporting form below:
- Chlamydia, gonorrhea, or syphilis
- Tuberculosis (cases & suspects)
- Latent TB infection
- All other reportable conditions
| Acquired Immunodeficiency Syndrome (AIDS) | Cysticercosis (Taenia solium) | Hepatitis, viral, Type Delta | *Mumps | Staphylococcus aureus, vancomycin resistance level of MIC ≥ 8 µg/mL or severe Staphylococcus aureus in a previously healthy person |
| *Animal Bites | ! Dengue | ! Hepatitis, viral, Type E | *Novel influenza A | Streptococcus pneumoniae, invasive disease and antimicrobial susceptibility testing |
| Anaplasmosis (Anaplasma species) | ! Diphtheria (Corynebacterium diphtheriae) | Hepatitis, viral, unspecified | *Pertussis (Bordetella pertussis) | Streptococcus, Group A, invasive disease (Streptococcus pyogenes) |
| ! Anthrax (Bacillus anthracis) | ! Eastern equine encephalitis (EEE) | Histoplasmosis (Histoplasma capsulatum) | ! Plague (Yersinia pestis) | Syphilis (Treponema pallidum) |
| ! Arboviral (Eastern Equine, St. Louis, La Crosse, West Nile, California, Western Equine, Powassan, Japanese) | Ehrlichiosis (Ehrlichia species) | HIV infection/disease (The following conditions related to HIV are laboratory reportable) Cryptococcus neoformans Kaposi’s sarcoma (biopsies) Pneumocystis carinii | ! Poliomyelitis | Tetanus (Clostridium tetani) |
| Babesiosis (Babesia species) | ! Escherichia coli infection (Shiga toxin‐ producing E. coli (STEC)) including, but not limited to: E. coli O157; E. coli O157:H7; Shiga toxin detected; or Non‐O157 E. coli | ! HIV infection/disease, pregnant woman or perinatally exposed infant | ! Powassan virus | Toxic shock syndrome (streptococcal or staphylococcal) |
| ! Botulism (Clostridium botulinum) | Giardiasis (Giardia species) | Influenza‐associated death (all ages) | Psittacosis (Chlamydia psittaci) | Trichinosis (Trichinella spiralis) |
| ! Brucellosis (Brucella species) | Gonorrhea (Neisseria gonorrheae) | ! Japanese encephalitis | ! Q Fever (Coxiella burnetti) | *Tuberculosis, cases, suspects, and latent infection (Mycobacterium tuberculosis) For latent infection, a positive screening test, negative or normal chest x‐ray, no evidence of extra‐pulmonary disease, and provider diagnosis are necessary. Report latent infection within five (5) business days. |
| Campylobacteriosis (Campylobacter species) | Granuloma inguinale (Calymmatobacterium granulomatis) | ! La Crosse encephalitis (California serogroup viruses) | ! Rabies in humans or animals, confirmed and suspect animal with human exposure | ! Tularemia (Francisella tularensis) |
| Carbapenemase‐producing Carbapenem‐ resistant Enterobacteriaceae (CP‐CRE) | *Haemophilus influenzae, invasive disease | Legionellosis (Legionella species) | Rabies, postexposure treatment | ! Typhoid and paratyphoid fever, cases and carriers (Salmonella Typhi or Paratyphi) |
| Chancroid (Haemophilus ducreyi) | Hansen’s disease (leprosy) (Mycobacterium leprae) | Leptospirosis (Leptospira species | Rocky Mountain spotted fever (Rickettsia species) | Typhus, endemic (flea‐borne) |
| ! Chikungunya virus | ! Hantavirus pulmonary syndrome | Listeriosis (Listeria monocytogenes, invasive) | ! Rubella (German Measles) | Varicella (chicken pox) |
| Chlamydia trachomatis, genital infection | ! Hemolytic uremic syndrome, postdiarrheal | Lyme disease (Borrelia burgdorferi) | ! Rubella congenital syndrome | Vibriosis (Vibrio species) |
| ! Cholera (Vibrio cholerae) | ! Hepatitis, viral, Type A | Lymphogranuloma venereum | Salmonellosis, non‐typhoidal (Salmonella species) | ! West Nile Virus (WNV) |
Coccidioidomycosis | Hepatitis, viral, Type B | Malaria (Plasmodium species) | ! Shigellosis (Shigella species) | ! Western equine encephalitis (WEE) |
*COVID-19, cases, deaths | ! Hepatitis, viral, Type B, pregnant woman (acute and chronic) or perinatally exposed infant | ! Measles (Rubeola) | ! Smallpox (Variola infection) Adverse events or complications due to smallpox vaccination (vaccinia virus infection) or secondary transmission to others after vaccination. | ! Yellow fever |
| Cryptosporidiosis (Cryptosporidium species) | Hepatitis, viral, Type C (acute), within five (5) business days | ! Meningococcal disease (Neisseria meningitidis, invasive) | ! St. Louis encephalitis (SLE) | Yersiniosis (Yersinia species) |
| Cyclosporiasis (Cyclospora cayetanensis) |
Upcoming Changes to Communicable Disease Reporting - 2022
Additional Resources
- 2015 Reportable Condition List (Edited 9/11/2020)
- HIPAA and Public Health Letter
- HIPAA Exemption
Page last updated: May 5, 2022